Table 1.

Comparison of clinicopathological characteristics between high- and low-neutrophil-to-lymphocyte groups n (%)

Clinicopathological feature	n	High-NLR group	Low-NLR group	χ2	P value
Gender				0.163	0.686
Male	210	93 (44.3)	117 (55.7)
Female	81	38 (46.9)	43 (53.1)
Age				12.377	0.000
< 65 yr	142	49 (34.5)	93 (65.5)
≥ 65 yr	149	82 (55.0)	67 (45.0)
Tumor size				20.852	0.000
< 5 cm	143	45 (31.5)	98 (68.5)
≥ 5 cm	148	86 (58.1)	62 (41.9)
Differentiation degree
Middle and high differentiation	130	59 (45.4)	71 (54.6)	0.013	0.910
Low differentiation	161	72 (44.7)	89 (55.3)
T staging
T1	20	2 (10.0)	18 (90.0)	20.731	0.000
T2	29	13 (41.4)	16 (58.6)
T3	177	74 (41.8)	103 (58.2)
T4	65	42 (64.6)	23 (35.4)
N staging				4.185	0.242
N0	55	18 (32.7)	37 (67.3)
N1	127	60 (47.2)	67 (52.8)
N2	78	38 (48.7)	40 (51.3)
N3	31	15 (48.4)	16 (51.6)
TNM staging				11.363	0.003
Stage I	32	8 (25.0)	24 (75.0)
Stage II	123	49 (39.8)	74 (60.2)
Stage III	136	74 (54.4)	62 (45.6)
platelet counting				9.672	0.002
< 300 × 109/L	253	105 (41.5)	148 (58.5)
≥ 300 × 109/L	38	26 (68.4)	12 (31.6)
CEA				2.972	0.085
< 5 ng/mL	178	73 (41.0)	105 (59.0)
≥ 5 ng/mL	113	58 (51.3)	55 (48.7)

NLR: Neutrophil-to-lymphocyte ratio; CEA: Carcinoembryonic antigen.